Asset Details
Do you wish to reserve the book?
Trial of Spesolimab for Generalized Pustular Psoriasis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Trial of Spesolimab for Generalized Pustular Psoriasis
Do you wish to request the book?
Trial of Spesolimab for Generalized Pustular Psoriasis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Trial of Spesolimab for Generalized Pustular Psoriasis
2021
Overview
In a randomized trial involving patients with the rare but disabling disorder generalized pustular psoriasis, the anti–interleukin-36 monoclonal antibody spesolimab greatly curtailed disease activity as compared with placebo over a period of 1 week. Systemic drug reactions and infections occurred with spesolimab.
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Allergy
/ Antibodies, Monoclonal, Humanized - administration & dosage
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Erythema
/ Female
/ Humans
/ Male
/ Mutation
/ Pain
/ Patients
/ Placebos
/ Receptors, Interleukin - antagonists & inhibitors
/ Skin
